Brookstone Capital Management
HZNP

Brookstone Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brookstone Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-170
Closed -$3K – 1006
2015
Q3 		$3K Hold
170
– – ﹤0.01% 1637
2015
Q2 		$6K Buy
+170
New +$5.19K ﹤0.01% 1439

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lone Pine Capital
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Investors US
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Brookstone Capital Management's HZNP Position: Q4 2015 in Review

Brookstone Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 170 shares — an estimated $3K sold.

Brookstone Capital Management first reported a position in HZNP in Q2 2015 and held it in 2 quarters. The position peaked at $6K in Q2 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

  • Brookstone Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 170 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $3K.
  • Brookstone Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 2 quarters.
  • Brookstone Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6K in Q2 2015.
  • 202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Brookstone Capital Management's 13F filing for Q4 2015, filed 14 Jan 2016.